Smooth Muscle Specific Inhibition for Anti-Restenotic Therapy

­Competitive Advantages

  • Prevents restenosis
  • Reduces inflammation
  • Reduces hypercoagulability
  • Preserves endothelial cell function

Summary

USF researchers have developed the first miRNA-based strategy to selectively inhibit VSMC proliferation and migration for the prevention of restenosis, without concurrently inhibiting reendothelialization and EC function. This was achieved by the design of a novel vector that inhibits VSMCs and selectively preserving ECs. This vector was shown to reduce hypercoagulation and restore EC function in vivo. The combination of a better stent platform and biodegradable polymer with this novel strategy, has the potential to revolutionize the future of vascular interventional medicine.

Novel Vector Reduces Hypercoagulability and Restores EC Function In Vivo

Desired Partnerships

  • License
  • Sponsored Research
  • Co-Development
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Smooth Muscle Specific Inhibition for Anti-Restenotic Therapy Utility WIPO PCT/US13/35327   4/4/2013    
Smooth Muscle Specific Inhibition for Anti-Restenotic Therapy Nationalized PCT United States 14/390,988   10/16/2014